| Auto-inflammatory diseases (AIDs) are a diverse group of disorders characterized by inappropriate activation of the innate immune system, leading to chronic inflammation. In children, these conditions can significantly impact multiple organs, including the kidneys. This review article is based on the most recent studies published after 2020, focusing on various auto-inflammatory diseases and their impact on kidney function. The review aims to provide a comprehensive overview of auto-inflammatory diseases and their renal involvement in pediatric patients, focusing on advancements in understanding the molecular mechanisms, diagnostic strategies, and treatment options. By examining the latest research, this article aims to enhance clinical awareness of renal manifestations and improve management strategies for pediatric rheumatologists. |
- Karabulut Y, Gezer HH, Duruöz MT. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment. Rheumatology International. 2022 Jan;42(1):81-6.
- Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolescent health, medicine and therapeutics. 2017 Nov 9:125-35.
- Brunner HI, Ruperto N, Zuber Z, Cuttica R, Keltsev V, Xavier RM, et al. Efficacy and safety of tocilizumab for polyarticular‐course juvenile idiopathic arthritis in the open‐label two‐year extension of a phase III trial. Arthritis & Rheumatology. 2021 Mar;73(3):530-41.
- Lopetuso LR, Cuomo C, Mignini I, Gasbarrini A, Papa A. Focus on anti-tumour necrosis factor (TNF)-α-related autoimmune diseases. International Journal of Molecular Sciences. 2023 May 3;24(9):8187.
- Del Giudice E, Sota J, Orlando F, Picciano L, Cimaz R, Cantarini L, et al. Off-label use of canakinumab in pediatric rheumatology and rare diseases. Frontiers in Medicine. 2022 Oct 18;9:998281.
- Horneff G, Minden K, Rolland C, Daly AC, Borlenghi C, Ruperto N. Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review. Pediatric Rheumatology. 2023 Feb 24;21(1):20.
- Lavalle S, Caruso S, Foti R, Gagliano C, Cocuzza S, La Via L, et al. Behçet’s disease, pathogenesis, clinical features, and treatment approaches: A comprehensive review. Medicina. 2024 Mar 29;60(4):562.
- Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. The Journal of rheumatology. 2014 Apr 1;41(4):759-67.
- Andronesi AG, Ismail G, Gherghiceanu M, Mitroi G, Hârza MC. Familial Mediterranean fever-associated renal amyloidosis: case report and review of the literature. Rom J Morphol Embryol. 2019 Jan 1;60(4):1299-303.
- Arnold DD, Yalamanoglu A, Boyman O. Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders. Frontiers in immunology. 2022 Jul 6;13:888392.
- Hegazy MT, Fayed A, Nuzzolese R, Sota J, Ragab G. Autoinflammatory diseases and the kidney. Immunologic Research. 2023 Aug;71(4):578-87.
- Koga T, Kawakami A. Interleukin-6 inhibition in the treatment of autoinflammatory diseases. Frontiers in Immunology. 2022 Jul 26;13:956795.
- Broderick L, Hoffman HM. IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nature Reviews Rheumatology. 2022 Aug;18(8):448-63.
- Jung SM, Kim WU. Targeted immunotherapy for autoimmune disease. Immune network. 2022 Feb 17;22(1):e9.
|
